MedTrace Logo

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

NCT03944785 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 164

Last updated 2023-06-07

Study results available
· View outcomes & findings →

Summary

This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.

Conditions

  • Idiopathic Parkinson Disease

Interventions

DRUG

XADAGO (safinamide)

XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.

Sponsors & Collaborators

  • Supernus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Najeebah Abdul-Musawir, MD,MBA · Supernus Pharmaceuticals, Inc.

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-30
Primary Completion
2019-12-23
Completion
2020-01-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03944785 on ClinicalTrials.gov